Health

EVŌQ Bio Announces Therapeutic Development Award from the Cystic Fibrosis Foundation

Leave a comment



SALT LAKE CITY (PRWEB)

EVŌQ Bio, (a division of EVŌQ Nano, LLC), an early-stage pharmaceutical company developing novel therapeutics against bacterial and fungal pathogens, today announced that it will receive US$378,500 to support the preclinical testing of its lead asset for the treatment of multi-drug resistant pulmonary bacterial infections in patients diagnosed with cystic fibrosis.

“Multi-drug resistant bacterial infections continue to have significant, deleterious impact on cystic fibrosis patients”, said David Nilson, Vice President of EVŌQ Bio. “Our novel therapeutic has the potential to be a first-line, stand-alone treatment against pseudomonas and burkholderia infections. The Cystic Fibrosis Foundation’s generous support and guidance is allowing us to move our technology forward in a way we believe will have significant impact to the cystic fibrosis community, as well as for those suffering from various forms of pulmonary bacterial infections.”

EVŌQ Bio’s poly-therapeutic platform leverages nano-technology in the development of antimicrobial applications ranging from pharmaceutical development to fungal/bacterial/biofilm inhibition in implanted/inserted medical devices. Our lead asset targets bacterial infections in the lungs, and its novel mechanism of action disrupts bacterial metabolic activity.

An earlier award from the Cystic Fibrosis Foundation in 2019 allowed us to confirm in vitro efficacy against nine bacteria (64 isolates) that include pseudomonas, staphylococcus, burkholderia and other gram-negative pathogens, while exhibiting no drug resistance. This award will fund dose range finding studies.

About EVŌQ Bio

EVŌQ Bio (a division of EVŌQ Nano, LLC) is an early-stage pharmaceutical company on a mission to develop treatments and technologies to reduce the global threat of multi-drug resistant infections. Our technology and unique mechanism of action enables treatment and prevention of bacterial disease, without contributing to the growing list of drug-resistant pathogens.

Share article on social media or email:

Leave a Reply